WAYNE, Pa., May 9 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) today announced that its Escalon Vascular Access subsidiary has
received positive feedback on the use of its redesigned Doppler Guided IV
Needle from a cancer center in a major hospital in Philadelphia.  After an
initial evaluation period, the cancer center has placed its first order.  The
PDAccess and its Doppler Guided IV Needle provide various benefits to the
clinician and patient, minimizing the need for multiple sticks and helping to
ensure central access to the intended vessel for infusion therapy.
Additionally, the use of the Doppler Guided Needle is very similar to the
clinician's traditional technique in accessing the veins of patients,
minimizing the learning curve.
    "We are very pleased with the feedback we have received from clinical
nurses and their staff about using our product," commented Richard J. DePiano,
Chairman and Chief Executive Officer.  "Clinical nurses are excited by our
Doppler Technology, which utilizes ultrasound for much easier targeting and
access to patients' veins.  This is particularly helpful in the area of
oncology, where patients must have their veins accessed frequently due to
cancer and chemotherapy treatment plans.  Based on our early results targeting
the oncology market, we will be expanding our focus to other cancer center
facilities in the Philadelphia and Mid-Atlantic region.  Our strategy will
include training and educating clinicians onsite in the cancer center in the
use of our Doppler Guided Needles."
    Mr. DePiano added, "The redesign of our Doppler Guided IV Needle is
expected to open many new market opportunities due to its flexibility in
application.  Some of its current uses are radial access for heart procedures,
accessing arterial vessels to monitor blood pressures in critical care unit
and operating room settings, and for delivering various infusion therapies and
anesthetics.  As part of our overall strategy for our Vascular Access
business, we will also continue to target other medical specialty areas that
would benefit from our proprietary technology while further filling the needs
of the oncology market.  Medical specialties we feel would benefit from this
technology are cardiac, radiology, electro physiology, hematology, oncology,
anesthesia, infusion therapy teams, intensive care units, and the operating
room."
    Escalon Vascular Access' new improved Doppler Guided IV Needle was well
received at its recent exhibition at the Oncology Nursing Society 27th Annual
Congress at the Washington Convention Center in Washington D.C. from
April 18-21.  The Congress experienced record attendance of over 6,000
professionals from the oncology and cancer care settings.
    Founded in 1987, Escalon develops, markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices.  The Company utilizes strategic partnerships to help finance its
development programs and is also seeking acquisitions to further diversify its
product line to achieve critical mass in sales and take better advantage of
the Company's distribution capabilities.  Escalon has headquarters in Wayne,
Pennsylvania and manufacturing operations in Long Island, New York and New
Berlin, Wisconsin.

    Note:  This press release contains statements that are forward-looking,
including statements about the Company's future prospects.  They are based on
the Company's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially.  The
uncertainties and risks include the manufacturing and market acceptance of new
products, marketing acceptance of existing products in new markets, whether
the Company is able to improve upon the operations of Sonomed, the vascular
access business and Escalon Medical Imaging, generate cash and identify,
finance and enter into business relationships and acquisitions, uncertainties
and risks related to new product development, research and development
activities, including failure to demonstrate clinical efficacy, delays by
regulatory authorities, scientific and technical advances by the Company or
third parties, introduction of competitive products, third party reimbursement
and physician training as well as general economic conditions.  Further
information about these and other relevant risks and uncertainties may be
found in the Company's report on Form 10-K, and its other filings with the
Securities and Exchange Commission, all of which are available from the
Commission as well as other sources.

Link to this page: